Published in Immunotherapy Weekly, August 31st, 2005
Approval of the designation was received less than 3 months after the company submitted its application, which required no revisions or amendments. Orphan drug designation is a necessary first step towards gaining regulatory approval for any product used to treat orphan patient populations.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.